A nucleic acid encoding at least one T cell receptor alpha chain construct and/or TCR beta chain construct of a TCR construct capable of specifically binding to an epitope from NY-ESO-1 consisting of SEQ ID:21 in complex with HLA-DR4, wherein the TCR alpha chain construct comprises a complementarity determining region CDR1 having an amino acid sequence of amino acids 46-51 of SEQ ID NO: 23, a CDR2 having an amino acid sequence of amino acids 69-74 of SEQ ID NO: 23 and a CDR3 having an amino acid sequence of amino acids 109-123 of SEQ ID NO: 23 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 59, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 59 and a CDR3 having an amino acid sequence of amino acids 111-125 of SEQ ID NO: 59, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 49-54 of SEQ ID NO: 22, a CDR2 having an amino acid sequence of amino acids 72-76 of SEQ ID NO: 22 and a CDR3 having an amino acid sequence of amino acids 111-123 of SEQ ID NO: 22 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 58, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 58 and a CDR3 having an amino acid sequence of amino acids 111-123 of SEQ ID NO: 58, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-51 of SEQ ID NO: 24, a CDR2 having an amino acid sequence of amino acids 69-75 of SEQ ID NO: 24 and a CDR3 having an amino acid sequence of amino acids 110-122 of SEQ ID NO: 24 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 60, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 60 and a CDR3 having an amino acid sequence of amino acids 111-124 of SEQ ID NO: 60, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-51 of SEQ ID NO: 25, a CDR2 having an amino acid sequence of amino acids 69-75 of SEQ ID NO: 25 and a CDR3 having an amino acid sequence of amino acids 110-123 of SEQ ID NO: 25 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 61, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 61 and a CDR3 having an amino acid sequence of amino acids 111-125 of SEQ ID NO: 61, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 45-49 of SEQ ID NO: 26, a CDR2 having an amino acid sequence of amino acids 67-72 of SEQ ID NO: 26 and a CDR3 having an amino acid sequence of amino acids 107-122 of SEQ ID NO: 26 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 62, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 62 and a CDR3 having an amino acid sequence of amino acids 111-122 of SEQ ID NO: 62, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 49-53 of SEQ ID NO: 27, a CDR2 having an amino acid sequence of amino acids 71-74 of SEQ ID NO: 27 and a CDR3 having an amino acid sequence of amino acids 109-121 of SEQ ID NO: 27 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 63, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 63 and a CDR3 having an amino acid sequence of amino acids 111-121 of SEQ ID NO: 63, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 49-53 of SEQ ID NO: 28, a CDR2 having an amino acid sequence of amino acids 71-74 of SEQ ID NO: 28 and a CDR3 having an amino acid sequence of amino acids 109-121 of SEQ ID NO: 28 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 64, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 64 and a CDR3 having an amino acid sequence of amino acids 111-121 of SEQ ID NO: 64, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 49-53 of SEQ ID NO: 29, a CDR2 having an amino acid sequence of amino acids 71-74 of SEQ ID NO: 29 and a CDR3 having an amino acid sequence of amino acids 109-121 of SEQ ID NO: 29 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 65, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 65 and a CDR3 having an amino acid sequence of amino acids 111-121 of SEQ ID NO: 65, or wherein the TCR alpha chain construct comprises a CDR1 having an amino acid sequence of amino acids 47-52 of SEQ ID NO: 30, a CDR2 having an amino acid sequence of amino acids 70-75 of SEQ ID NO: 30 and a CDR3 having an amino acid sequence of amino acids 110-122 of SEQ ID NO: 30 and/or the TCR beta chain construct comprises a CDR1 having an amino acid sequence of amino acids 46-50 of SEQ ID NO: 66, a CDR2 having an amino acid sequence of amino acids 68-73 of SEQ ID NO: 66 and a CDR3 having an amino acid sequence of amino acids 111-126 of SEQ ID NO: 66.